secwatch.observer — SEC 8-K summary
======================================

Issuer:     HARROW, INC. (HROW)
CIK:        0001360214
Form:       8-K
Filed at:   2026-02-02T23:59:59+00:00
Accession:  0001493152-26-004635
Event type: earnings
Sentiment:  positive
Materiality: 0.60
Item codes: 2.02, 5.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Harrow reaffirms 2025 revenue guidance of $270-280M, promotes Sullivan to CCO, settles CA regulatory matters
--------------------------------------------------------------------------------

- Reaffirmed FY2025 revenue guidance of $270-280 million; full-year results expected in early March.
- Patrick Sullivan promoted to CCO; $425k base salary, 40% target bonus, 40,000 RSUs vesting on $230M quarterly branded revenue.
- VEVYE sales force to double to ~100 territories by Memorial Day; TRIESENCE surgical sales force also doubling.
- ImprimisRx settled with CA Board of Pharmacy for ~$157k fine and voluntarily exited CA market; not financially material.
- MELT-300 NDA submission on track for H1 2027; MELT-210 NDA on track.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1360214/000149315226004635/0001493152-26-004635-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1360214/000149315226004635/form8-k.htm
  HTML page:      https://secwatch.observer/filing/0001493152-26-004635

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer